Other

University of Washington

The University of Costa Rica

Eric D Lynch

Mary-Claire King

Pedro E Leon

Jan E Morrow

Ming K Lee

Piri L Welcsh

An apparatus for authenticating a user to gain access or entry. A correct final time interval count is associated with execution of a secure system act; it is revealed to or known by the user prior to ending the secure system act. A counter determines a final time interval count representing a number of time intervals from the beginning to the end of the secure system act. A validation unit validates the user as a valid user if the secure system act matches a correct secure system act and the final time interval count matches a correct final time interval count. If both determinations are affirmative the validation unit produces an authentication signal. In turn a control unit generates a control signal that permits access or entry to the user.

Temporal security for controlled access systems

A method for gaining access or entry to a system. The method comprises (a) beginning a secure system act by a user; (b) beginning counting of time intervals concurrent with execution of step (a); (c) ending the secure system act by the user; (d) capturing a final time interval count concurrent with execution of step (c); (e) determining whether the secure system act matches a correct secure system act; (d) determining whether the final time interval count matches a correct final time interval count; and (e) granting the user access or entry to the system responsive affirmative results of step (d).

The invention provides methods and compositions which find use, inter alia, for modulating the stabilization of actin filaments. The compositions may comprise one or more polypeptide moieties derived from a novel human diaphanous polypeptide and/or one or more nucleic acid moieties derived from a novel human diaphanous gene or gene transcript. The invention also provides agents which specifically modify the binding of a natural human diaphanous gene or gene product with a natural binding target thereof, isolated human diaphanous hybridization probes and primers capable of specifically hybridizing with the disclosed human diaphanous genes, human diaphanous-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.

Growing community of inventors

Seattle, WA, United States of America

Eric D Lynch